From rxpgnews.com
Chief scientific officer named first Richard L. Menschel Research Chair at Special Surgery
By Hospital for Special Surgery,
Dec 13, 2011 - 5:00:00 AM
Steven R. Goldring, M.D., chief scientific officer, has been named the first Richard L. Menschel Research Chair at Hospital for Special Surgery. A gift of $5 million from an anonymous donor will permanently endow the position of the Hospital's chief scientific officer.
This chair honors Richard L. Menschel, Hospital for Special Surgery chairman emeritus and a senior director, The Goldman Sachs Group, L.P., who has been a vital proponent of the Hospital's focus on research. In addition to providing leadership for the HSS Reseach Division, Dr. Goldring's research objective is to translate basic research into new therapies for people with mobility disorders, with a focus on expanding the Hospital's clinical registries and advancing its Osteoarthritis Initiative.
Extraordinary advances in medicine can be accomplished when there are partnerships between visionary leaders like Richard Menschel and scientific innovators like Dr. Steven Goldring, said Louis A. Shapiro, president and CEO of Hospital for Special Surgery.
Dr. Goldring is a strong advocate of the physician-scientist. He has led the recruitment of talented scientists in the areas of arthritis and tissue degeneration, autoimmunity and inflammation, musculoskeletal integrity, and tissue engineering, regeneration and repair.
I am truly honored to be the first holder of the Richard L. Menschel Research Chair at Hospital for Special Surgery, said Dr. Goldring. I began my career as a clinician, but I was also fortunate enough to be in an environment that supported and promoted the great importance of research. While our focus is how best to define disease mechanisms, the ultimate goal is to apply what we learn to patient care.
A major initiative that Dr. Goldring will oversee is the expansion of Hospital for Special Surgery's clinical patient registries. These powerful research tools provide the foundation of clinical trials, providing an ongoing collection of confidential clinical and demographic information that can be analyzed to examine health care issues that are critical to understanding the outcome of patient care and refining treatments.
During his tenure Dr. Goldring has taken the Research Division to new levels, said Thomas Sculco, M.D., surgeon-in-chief at Hospital for Special Surgery. His exceptional background as a physician and researcher in arthritic conditions and bone and joint disorders makes him uniquely qualified to lead the Hospital in all areas of investigation.
A priority for any first-rate medical institution is to have a world-class research program, said Mr. Menschel. Dr. Goldring has led Hospital for Special Surgery into a new era of clinical and translational research.
All rights reserved by RxPG Medical Solutions Private Limited ( www.rxpgnews.com )